Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0QB1O
|
|||
Drug Name |
CD19 and CD20 CAR-T Cells
|
|||
Drug Type |
CAR T Cell Therapy (Dual specific)
|
|||
Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1/2 | [1] | |
leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1/2 | [1] | ||
Company |
Chinese PLA General Hospital
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | CAR-T-Cell-Therapy(Dual specific) | [1] |
Leukocyte surface antigen Leu-16 (CD20) | Target Info | CAR-T-Cell-Therapy(Dual specific) | [1] | |
KEGG Pathway | Hematopoietic cell lineage | |||
PI3K-Akt signaling pathway | ||||
B cell receptor signaling pathway | ||||
Epstein-Barr virus infection | ||||
Primary immunodeficiency | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
Panther Pathway | B cell activation | |||
Pathway Interaction Database | BCR signaling pathway | |||
Reactome | PIP3 activates AKT signaling | |||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
WikiPathways | Human Complement System | |||
Signaling by the B Cell Receptor (BCR) | ||||
PIP3 activates AKT signaling | ||||
B Cell Receptor Signaling Pathway | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.